BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $753,037 | -66.2% | 18,566 | -57.5% | 0.00% | -40.0% |
| Q4 2022 | $2,227,746 | -66.2% | 43,707 | -64.3% | 0.01% | -61.5% |
| Q3 2022 | $6,593,000 | +1118.7% | 122,407 | +1352.6% | 0.01% | +1200.0% |
| Q2 2022 | $541,000 | -44.5% | 8,427 | -33.0% | 0.00% | 0.0% |
| Q1 2022 | $975,000 | -67.5% | 12,574 | -64.0% | 0.00% | -50.0% |
| Q4 2021 | $3,002,000 | -12.7% | 34,974 | -18.2% | 0.00% | -50.0% |
| Q3 2021 | $3,440,000 | +54.6% | 42,774 | +54.8% | 0.00% | +33.3% |
| Q2 2021 | $2,225,000 | +1077.2% | 27,638 | +1079.1% | 0.00% | +200.0% |
| Q3 2020 | $189,000 | +243.6% | 2,344 | +268.6% | 0.00% | – |
| Q2 2020 | $55,000 | -69.3% | 636 | -70.3% | 0.00% | -100.0% |
| Q4 2019 | $179,000 | -31.2% | 2,139 | -28.0% | 0.00% | -50.0% |
| Q3 2019 | $260,000 | +14.5% | 2,971 | +7.3% | 0.00% | 0.0% |
| Q2 2019 | $227,000 | -32.0% | 2,769 | -45.5% | 0.00% | -33.3% |
| Q4 2018 | $334,000 | +1987.5% | 5,077 | +2388.7% | 0.00% | – |
| Q3 2018 | $16,000 | -89.9% | 204 | -92.2% | 0.00% | -100.0% |
| Q2 2017 | $159,000 | +7.4% | 2,630 | -8.0% | 0.00% | 0.0% |
| Q1 2017 | $148,000 | -52.6% | 2,858 | -36.5% | 0.00% | -75.0% |
| Q2 2013 | $312,000 | – | 4,499 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |